Erratum: Cutting Edge: FcgRIII (CD16) and FcgRI (CD64) are responsible for anti-glycoprotein 75 monoclonal antibody TA99 therapy for experimental metastatic B16 melanoma (The Journal of Immunology (2012) 189 (5513-5517))

Marcello Albanesi; David A. Mancardi; Lynn E. Macdonald; Bruno Iannascoli; Laurence Zitvogel; Andrew J. Murphy; Marc Daëron; Jeanette H. Leusen; Pierre Bruhns

doi:10.4049/jimmunol.1290083

Erratum: Cutting Edge: FcgRIII (CD16) and FcgRI (CD64) are responsible for anti-glycoprotein 75 monoclonal antibody TA99 therapy for experimental metastatic B16 melanoma (The Journal of Immunology (2012) 189 (5513-5517))

Marcello Albanesi^*
, David A. Mancardi
, Lynn E. Macdonald
, Bruno Iannascoli
, Laurence Zitvogel
, Andrew J. Murphy
, Marc Daëron
, Jeanette H. Leusen
, Pierre Bruhns

^*Corresponding author for this work

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

Original language	English
Pages (from-to)	1381
Number of pages	1
Journal	Journal of Immunology
Volume	190
Issue number	3
DOIs	https://doi.org/10.4049/jimmunol.1290083
Publication status	Published - 1 Feb 2013

Access to Document

10.4049/jimmunol.1290083

Cite this

Albanesi, M., Mancardi, D. A., Macdonald, L. E., Iannascoli, B., Zitvogel, L., Murphy, A. J., Daëron, M., Leusen, J. H., & Bruhns, P. (2013). Erratum: Cutting Edge: FcgRIII (CD16) and FcgRI (CD64) are responsible for anti-glycoprotein 75 monoclonal antibody TA99 therapy for experimental metastatic B16 melanoma (The Journal of Immunology (2012) 189 (5513-5517)). Journal of Immunology, 190(3), 1381. https://doi.org/10.4049/jimmunol.1290083

@article{ef3912b7adb3461da7a3122be9ddaf88,

title = "Erratum: Cutting Edge: FcgRIII (CD16) and FcgRI (CD64) are responsible for anti-glycoprotein 75 monoclonal antibody TA99 therapy for experimental metastatic B16 melanoma (The Journal of Immunology (2012) 189 (5513-5517))",

author = "Marcello Albanesi and Mancardi, \{David A.\} and Macdonald, \{Lynn E.\} and Bruno Iannascoli and Laurence Zitvogel and Murphy, \{Andrew J.\} and Marc Da{\"e}ron and Leusen, \{Jeanette H.\} and Pierre Bruhns",

year = "2013",

month = feb,

day = "1",

doi = "10.4049/jimmunol.1290083",

language = "English",

volume = "190",

pages = "1381",

journal = "Journal of Immunology",

issn = "0022-1767",

publisher = "American Association of Immunologists",

number = "3",

}

Albanesi, M, Mancardi, DA, Macdonald, LE, Iannascoli, B, Zitvogel, L, Murphy, AJ, Daëron, M, Leusen, JH & Bruhns, P 2013, 'Erratum: Cutting Edge: FcgRIII (CD16) and FcgRI (CD64) are responsible for anti-glycoprotein 75 monoclonal antibody TA99 therapy for experimental metastatic B16 melanoma (The Journal of Immunology (2012) 189 (5513-5517))', Journal of Immunology, vol. 190, no. 3, pp. 1381. https://doi.org/10.4049/jimmunol.1290083

Erratum: Cutting Edge: FcgRIII (CD16) and FcgRI (CD64) are responsible for anti-glycoprotein 75 monoclonal antibody TA99 therapy for experimental metastatic B16 melanoma (The Journal of Immunology (2012) 189 (5513-5517)). / Albanesi, Marcello; Mancardi, David A.; Macdonald, Lynn E. et al.
In: Journal of Immunology, Vol. 190, No. 3, 01.02.2013, p. 1381.

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

TY - JOUR

T1 - Erratum

T2 - Cutting Edge: FcgRIII (CD16) and FcgRI (CD64) are responsible for anti-glycoprotein 75 monoclonal antibody TA99 therapy for experimental metastatic B16 melanoma (The Journal of Immunology (2012) 189 (5513-5517))

AU - Albanesi, Marcello

AU - Mancardi, David A.

AU - Macdonald, Lynn E.

AU - Iannascoli, Bruno

AU - Zitvogel, Laurence

AU - Murphy, Andrew J.

AU - Daëron, Marc

AU - Leusen, Jeanette H.

AU - Bruhns, Pierre

PY - 2013/2/1

Y1 - 2013/2/1

UR - https://www.scopus.com/pages/publications/84872692876

U2 - 10.4049/jimmunol.1290083

DO - 10.4049/jimmunol.1290083

M3 - Comment/Letter to the editor

AN - SCOPUS:84872692876

SN - 0022-1767

VL - 190

SP - 1381

JO - Journal of Immunology

JF - Journal of Immunology

IS - 3

ER -

Albanesi M, Mancardi DA, Macdonald LE, Iannascoli B, Zitvogel L, Murphy AJ et al. Erratum: Cutting Edge: FcgRIII (CD16) and FcgRI (CD64) are responsible for anti-glycoprotein 75 monoclonal antibody TA99 therapy for experimental metastatic B16 melanoma (The Journal of Immunology (2012) 189 (5513-5517)). Journal of Immunology. 2013 Feb 1;190(3):1381. doi: 10.4049/jimmunol.1290083

Erratum: Cutting Edge: FcgRIII (CD16) and FcgRI (CD64) are responsible for anti-glycoprotein 75 monoclonal antibody TA99 therapy for experimental metastatic B16 melanoma (The Journal of Immunology (2012) 189 (5513-5517))

Access to Document

Other files and links

Cite this